Ibrutinib has some activity in Richter’s syndrome
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
http://www.nature.com/articles/bcj201498.pdf
Reference10 articles.
1. Parikh SA, Kay NE, Shanafelt TD . How we treat Richter syndrome. Blood 2014; 123: 1647–1657.
2. Dabaja BS, O'Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma 2001; 42: 329–337.
3. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003; 97: 1711–1720.
4. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM et al. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma 2002; 43: 767–772.
5. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008; 26: 196–203.
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia;Leukemia & Lymphoma;2024-09-02
2. Richter's transformation: Transforming the clinical landscape;Blood Reviews;2023-12
3. Practical Management of Richter Transformation in 2023 and Beyond;American Society of Clinical Oncology Educational Book;2023-01
4. Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia;International Journal of Molecular Sciences;2022-11-17
5. Richter Syndrome: From Molecular Pathogenesis to Druggable Targets;Cancers;2022-09-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3